ArticleFrontiers in immunology2026
Breast and ovarian cancers: toward a multi-cancer early detection test.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer (BC) and ovarian cancer (OC) are leading causes of cancer-related mortality among women worldwide. Despite their distinct clinical presentation these malignancies share genetic, hormonal, and micro-environmental characteristics, suggesting overlapping mechanisms of tumorigenesis and immune escape. Identifying common immune-related biomarkers could improve large scale early detection and guide the development of shared therapeutic strategies. Methods: We conducted a multiplex immunoassay profiling of 81 immune-related proteins including cytokines, chemokines, growth factors, and immune checkpoints in serum samples from 57 BC patients, 57 OC patients, and 49 healthy controls (HC). Results: Multivariate and univariate analyses were utilized to identify proteins exhibiting significant dysregulation. Receiver Operating Characteristic (ROC) curve analyses were conducted to evaluate the diagnostic performance of individual and combined protein panels. Protein-protein interaction networks were constructed using STRING and Cytoscape to elucidate shared functional modules. Multivariate analysis revealed a partial yet significant distinction between cancer patients and HC, with BC and OC exhibiting notable immunological similarities. Eighteen proteins were dysregulated in BC and OC as compared to HC, indicating shared oncogenic and immunological pathways. Furthermore, individual biomarkers exhibited moderate diagnostic performance, while combined panels achieved high accuracy. Network analysis revealed highly interconnected modules centered on the TNF/TNFR superfamily, co-stimulatory molecules, and chemokines, suggesting promising targets for combinatorial immunotherapy. Disscussion: our findings demonstrate a significant overlap in immune-related protein expression between BC and OC, supporting the feasibility of a common diagnostic biomarker panel for these female cancers. The identified proteins and their interaction networks offer valuable insights into the shared mechanisms of tumor progression and immune evasion, presenting promising avenues for early diagnosis and targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.